OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CITR55

Citurgia Biochemicals Ltd

Commodity ChemicalsVerified

Citurgia Biochemicals Ltd exhibits a highly leveraged capital structure, with total liabilities of ₹176.10 million and total equity of -₹65.69 million, resulting in a negative debt-to-equity ratio of -1.03. The company's liquidity position is weak, as evidenced by a current ratio of 0.92 and negative net cash after subtracting total debt. Operating cash flow is negative at -₹1.42 million, further highlighting the company's cash flow challenges. Profitability metrics are severely underperforming relative to industry norms. The company reported a net loss of ₹18.13 million and an operating loss of ₹18.12 million, with a return on assets of -1.64% and a return on equity of 2.76%. These figures indicate a significant underperformance compared to the industry's preferred metrics, which typically emphasize positive returns and stable operating margins. The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification. This opacity increases the risk of overreliance on a single market or product line, which could be vulnerable to sector-specific downturns. Growth prospects are constrained by the company's current financial position. The outlook for the current fiscal year shows no improvement in revenue, and the next fiscal year is expected to remain flat. The company's historical revenue is reported as zero, which may indicate a recent listing or a restructuring event. The absence of positive revenue growth signals a lack of momentum in the business. Risk factors include a high liquidity risk due to negative net cash and a weak operating cash flow. The company's equity is negative, and its debt load is substantial, with long-term debt of ₹67.70 million. While dilution risk is currently assessed as low, the company's financial position could deteriorate, potentially leading to equity dilution through new financing or recapitalization. Recent events include the company's financial reporting, which shows a consistent pattern of losses and negative cash flows. No recent filings or transcripts are available to provide additional context on management's strategy or operational changes.

30-day price · CITR-109.70 (-53.9%)
Low$84.75High$212.00Close$93.65As of11 May, 00:00 UTC
Profile
CompanyCiturgia Biochemicals Ltd
TickerCITR.BO
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Citurgia Biochemicals Ltd is a chemical manufacturing company that produces and sells commodity chemicals, primarily serving industrial and consumer markets.

Classification. Citurgia Biochemicals Ltd is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a confidence level of 0.92 based on verified market data.

Citurgia Biochemicals Ltd exhibits a highly leveraged capital structure, with total liabilities of ₹176.10 million and total equity of -₹65.69 million, resulting in a negative debt-to-equity ratio of -1.03. The company's liquidity position is weak, as evidenced by a current ratio of 0.92 and negative net cash after subtracting total debt. Operating cash flow is negative at -₹1.42 million, further highlighting the company's cash flow challenges. Profitability metrics are severely underperforming relative to industry norms. The company reported a net loss of ₹18.13 million and an operating loss of ₹18.12 million, with a return on assets of -1.64% and a return on equity of 2.76%. These figures indicate a significant underperformance compared to the industry's preferred metrics, which typically emphasize positive returns and stable operating margins. The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification. This opacity increases the risk of overreliance on a single market or product line, which could be vulnerable to sector-specific downturns. Growth prospects are constrained by the company's current financial position. The outlook for the current fiscal year shows no improvement in revenue, and the next fiscal year is expected to remain flat. The company's historical revenue is reported as zero, which may indicate a recent listing or a restructuring event. The absence of positive revenue growth signals a lack of momentum in the business. Risk factors include a high liquidity risk due to negative net cash and a weak operating cash flow. The company's equity is negative, and its debt load is substantial, with long-term debt of ₹67.70 million. While dilution risk is currently assessed as low, the company's financial position could deteriorate, potentially leading to equity dilution through new financing or recapitalization. Recent events include the company's financial reporting, which shows a consistent pattern of losses and negative cash flows. No recent filings or transcripts are available to provide additional context on management's strategy or operational changes.
Key takeaways
  • Citurgia Biochemicals Ltd is highly leveraged with a negative equity position and weak liquidity.
  • The company is unprofitable, with significant operating and net losses.
  • Revenue concentration and growth trajectory are unclear due to limited data.
  • Liquidity and solvency risks are elevated, with no clear path to profitability.
  • The company's financial position suggests a high risk of further deterioration without significant operational or strategic changes.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$0.00
Gross profit
Operating income-$1.8M
Net income-$1.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$1.4M
CapEx
Free cash flow
Total assets$110.4M
Total liabilities$176.1M
Total equity-$65.7M
Cash & equivalents$1.0M
Long-term debt$67.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$0.00-$6.1M-$6.1M-$3.7M
FY-3$0.00-$4.0M-$4.0M-$1.8M
FY-2$0.00-$4.4M-$4.4M-$2.1M
FY-1$0.00-$4.8M-$4.8M-$2.5M
FY0$0.00-$4.2M-$4.2M-$2.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$116.0M-$52.5M$684.8k
FY-3$114.3M-$56.6M$539.7k
FY-2$111.9M-$60.9M$783.9k
FY-1$110.4M-$65.7M$1.0M
FY0$107.6M-$69.9M$1.2M
PeriodOCFCapExFCFSBC
FY-4-$1.5M-$3.7M
FY-3-$285.1k-$1.8M
FY-2-$675.9k-$2.1M
FY-1-$1.4M-$2.5M
FY0-$1.2M-$2.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$0.00-$1.8M-$1.8M
FQ-6$0.00-$900.0k-$900.0k
FQ-5$0.00-$1.4M-$1.4M
FQ-4$0.00-$1.0M-$1.0M
FQ-3$0.00-$825.2k-$826.8k
FQ-2$0.00-$839.0k-$839.0k
FQ-1$0.00-$1.1M-$1.1M
FQ0$0.00-$2.9M-$2.9M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$110.4M-$65.7M$1.0M
FQ-6
FQ-5$106.4M-$67.7M$1.2M
FQ-4
FQ-3$107.6M-$69.9M$1.2M
FQ-2
FQ-1$104.9M-$73.3M$1.4M
FQ0
PeriodOCFCapExFCFSBC
FQ-7-$1.4M
FQ-6
FQ-5-$3.6M
FQ-4
FQ-3-$1.2M
FQ-2
FQ-1-$1.1M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$65.7M
Net cash-$66.6M
Current ratio0.9
Debt/Equity-1.0
ROA-1.6%
ROE2.8%
Cash conversion78.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricCITRActivity
Op margin5.5% medp25 -0.0% · p75 10.8%
Net margin4.1% medp25 0.1% · p75 8.8%
Gross margin20.5% medp25 12.4% · p75 29.7%
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-6.2% medp25 -13.4% · p75 -2.6%
Debt / equity-103.0%37.1% medp25 10.3% · p75 82.0%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 01:04 UTC#93af9e7b
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 15:46 UTCJob: 2fd80a61